share_log

Oppenheimer Reiterates Outperform on ArriVent BioPharma, Maintains $35 Price Target

Benzinga ·  Aug 15 21:53  · Ratings

Oppenheimer analyst Jeff Jones reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and maintains $35 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment